These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population. Lichtensztajn DY; Leppert JT; Brooks JD; Shah SA; Sieh W; Chung BI; Gomez SL; Cheng I J Natl Compr Canc Netw; 2018 Nov; 16(11):1353-1360. PubMed ID: 30442735 [No Abstract] [Full Text] [Related]
4. Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer. Gray PJ; Lin CC; Cooperberg MR; Jemal A; Efstathiou JA Eur Urol; 2017 May; 71(5):729-737. PubMed ID: 27597241 [TBL] [Abstract][Full Text] [Related]
5. Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. Schmid M; Meyer CP; Reznor G; Choueiri TK; Hanske J; Sammon JD; Abdollah F; Chun FK; Kibel AS; Tucker-Seeley RD; Kantoff PW; Lipsitz SR; Menon M; Nguyen PL; Trinh QD JAMA Oncol; 2016 Jan; 2(1):85-93. PubMed ID: 26502115 [TBL] [Abstract][Full Text] [Related]
6. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort. Du XL; Fang S; Coker AL; Sanderson M; Aragaki C; Cormier JN; Xing Y; Gor BJ; Chan W Cancer; 2006 Mar; 106(6):1276-85. PubMed ID: 16475208 [TBL] [Abstract][Full Text] [Related]
7. Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer: data from CaPSURE. Latini DM; Elkin EP; Cooperberg MR; Sadetsky N; Duchane J; Carroll PR Cancer; 2006 Feb; 106(4):789-95. PubMed ID: 16400651 [TBL] [Abstract][Full Text] [Related]
8. Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study. Hoffman RM; Harlan LC; Klabunde CN; Gilliland FD; Stephenson RA; Hunt WC; Potosky AL J Gen Intern Med; 2003 Oct; 18(10):845-53. PubMed ID: 14521648 [TBL] [Abstract][Full Text] [Related]
9. Racial disparities in survival for patients with clinically localized prostate cancer adjusted for treatment effects. Tyson MD; Castle EP Mayo Clin Proc; 2014 Mar; 89(3):300-7. PubMed ID: 24582189 [TBL] [Abstract][Full Text] [Related]
10. A population-based analysis of contemporary patterns of care in younger men (<60 years old) with localized prostate cancer. Wong AT; Safdieh JJ; Rineer J; Weiner J; Schwartz D; Schreiber D Int Urol Nephrol; 2015 Oct; 47(10):1629-34. PubMed ID: 26329748 [TBL] [Abstract][Full Text] [Related]
11. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Klabunde CN; Potosky AL; Harlan LC; Kramer BS Med Care; 1998 Sep; 36(9):1337-48. PubMed ID: 9749657 [TBL] [Abstract][Full Text] [Related]
12. Hospital racial composition and the treatment of localized prostate cancer. Pollack CE; Bekelman JE; Liao KJ; Armstrong K Cancer; 2011 Dec; 117(24):5569-78. PubMed ID: 21692067 [TBL] [Abstract][Full Text] [Related]
13. Sociodemographic factors associated with prostatectomy utilization and concordance with the physician data query for prostate cancer (United States). Morris CR; Snipes KP; Schlag R; Wright WE Cancer Causes Control; 1999 Dec; 10(6):503-11. PubMed ID: 10616820 [TBL] [Abstract][Full Text] [Related]
14. Racial disparities in lymph node dissection at radical prostatectomy: A Surveillance, Epidemiology and End Results database analysis. Preisser F; Nazzani S; Bandini M; Marchioni M; Tian Z; Saad F; Chun FK; Shariat SF; Montorsi F; Huland H; Graefen M; Tilki D; Karakiewicz PI Int J Urol; 2018 Nov; 25(11):929-936. PubMed ID: 30146729 [TBL] [Abstract][Full Text] [Related]
15. Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer. Shavers VL; Brown M; Klabunde CN; Potosky AL; Davis W; Moul J; Fahey A Med Care; 2004 Mar; 42(3):239-50. PubMed ID: 15076823 [TBL] [Abstract][Full Text] [Related]
16. Understanding variation in primary prostate cancer treatment within the Veterans Health Administration. Nambudiri VE; Landrum MB; Lamont EB; McNeil BJ; Bozeman SR; Freedland SJ; Keating NL Urology; 2012 Mar; 79(3):537-45. PubMed ID: 22245306 [TBL] [Abstract][Full Text] [Related]
17. Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. Moses KA; Paciorek AT; Penson DF; Carroll PR; Master VA J Clin Oncol; 2010 Feb; 28(6):1069-74. PubMed ID: 20100957 [TBL] [Abstract][Full Text] [Related]
18. Penile implant utilization following treatment for prostate cancer: analysis of the SEER-Medicare database. Tal R; Jacks LM; Elkin E; Mulhall JP J Sex Med; 2011 Jun; 8(6):1797-804. PubMed ID: 21426495 [TBL] [Abstract][Full Text] [Related]
19. Predictors of aggressive therapy for nonmetastatic prostate carcinoma in Massachusetts from 1998 to 2002. Rose AJ; Backus BM; Gershman ST; Santos P; Ash AS; Battaglia TA Med Care; 2007 May; 45(5):440-7. PubMed ID: 17446830 [TBL] [Abstract][Full Text] [Related]
20. Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study. Tyson MD; Alvarez J; Koyama T; Hoffman KE; Resnick MJ; Wu XC; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Paddock LE; Stroup A; Chen VW; Penson DF; Barocas DA Eur Urol; 2017 Aug; 72(2):307-314. PubMed ID: 27816300 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]